lymphoid cells

[Immune-Onc Therapeutics, Inc.] Immune-Onc Therapeutics, Inc. announced that the first patient has been dosed in the company’s first-in-human clinical trial of IO-108, a novel antagonist antibody targeting the myeloid checkpoint Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) for the treatment of solid tumors.

[Proceedings of the National Academy of Sciences of the United States of America] Scientists examined the tRNA and mRNA pools of T cells during their vigorous proliferation and differentiation upon triggering their antigen receptor.

[Nanoscale] The immunosuppressive tumor microenvironment has become a formidable obstacle to the treatment of tumors using adoptive T cell therapy, in particular solid tumors. Effector OT-1 CD8+T cells conjugated with liposomal immune regulators were developed to address this issue.

[Journal of Experimental & Clinical Cancer Research] Alloantigen-activated CD4+ T cells were generated from CD4+ T cells isolated from BALB/c mice in cultures with dendritic cells induced from C57BL/6 mice.

[Breast Cancer Research] Scientists investigated the effect of oestrogen deprivation on the expression of chemokines and immune infiltration in vitro and in an ER+ immunocompetent mouse model.

[Communications Biology] Scientists demonstrated that expanded human Tregs switch their metabolism to aerobic glycolysis and show enhanced suppressive function through hypoxia-inducible factor 1-alpha driven acquisition of CD73 expression.